Welcome to our dedicated page for Fresenius Med Cr news (Ticker: FMS), a resource for investors and traders seeking the latest updates and insights on Fresenius Med Cr stock.
Fresenius Medical Care AG (FMS) is widely described as the world's leading provider of products and services for individuals with renal disease, and its news flow reflects this focus on kidney care. Through thousands of dialysis clinics and a broad range of dialysis products, the company regularly reports on developments that are relevant to patients, clinicians, and investors following the kidney dialysis sector.
News about Fresenius Medical Care often covers its financial performance and strategic programs. The company issues quarterly updates on organic revenue growth, operating income, margins, cash flow, and net leverage ratio. These releases also describe the progress of its FME25+ transformation program and the FME Reignite strategy, which target savings, margin expansion, and portfolio optimization. Investors can follow announcements on divestments of selected clinic operations and the impact of these actions on revenue growth and profitability.
Another recurring theme in FMS news is capital allocation. Fresenius Medical Care has announced an initial share buyback program with a total volume of EUR 1 billion, implemented in tranches. Press releases detail the launch, execution, and acceleration of these tranches, as well as the company’s rationale for returning excess capital to shareholders under its capital allocation framework.
On the clinical and innovation side, Fresenius Medical Care publishes updates on dialysis therapies, technologies, and research. Recent news has highlighted high-volume hemodiafiltration (HighVolumeHDF), regulatory clearances for the 5008X Hemodialysis System and the 5008X CAREsystem, and collaborations to expand access to advanced dialysis therapies in markets such as Mexico. The company also shares research presented at nephrology conferences, including studies on hemodiafiltration outcomes and the use of artificial intelligence in dialysis care.
Additional news items cover leadership appointments, especially within the Management Board and operating segments such as Care Enablement and Value-Based Care, as well as investments in Interwell Health and genomics initiatives through Frenova and Nephronomics. Users interested in FMS can monitor this page for ongoing updates on financial results, strategic moves, clinical research, and corporate governance developments related to Fresenius Medical Care.
Fresenius Medical Care (NYSE:FMS) announced a strategic collaboration between its research organization Frenova, Nephronomics, and GENEWIZ by Azenta Life Sciences to advance genomic analysis of kidney disease through the My Reason® genomics program.
The collaboration leverages Frenova's registry of over 35,000 participants (targeting 50,000 in two years) to create the world's largest cardio-kidney-metabolic disease database. GENEWIZ will provide DNA sequencing and biospecimen storage, while Nephronomics holds exclusive commercial rights to develop targeted therapies using AI/ML models.
This initiative aims to transform kidney care through personalized medicine by analyzing genetic mechanisms underlying kidney, cardiovascular, and metabolic diseases.
Fresenius Medical Care (NYSE:FMS), the global leader in renal disease products and services, has expanded its High-Volume Hemodiafiltration (HighVolumeHDF) therapy in Mexico through a partnership with CCINSHAE. The two-year contract includes installing 150 Fresenius Medical Care 5008S CorDiax systems across seven CCINSHAE centers in Mexico City.
The program now treats 240 new uninsured CCINSHAE patients and 410 regular insured patients. Clinical studies, including the CONVINCE Trial, showed HighVolumeHDF therapy reduces all-cause mortality by 23% compared to standard high-flux hemodialysis. Following FDA clearance of its 5008X CAREsystem in May 2025, Fresenius plans to launch HighVolumeHDF in the U.S. market by 2026.
Fresenius Medical Care (FMS) reported strong Q1 2025 results with 5% organic revenue growth to EUR 4,881 million. The company's operating income grew significantly by 35% to EUR 331 million, while net income more than doubled with a 113% increase to EUR 151 million. Key highlights include:
The FME25 transformation program delivered EUR 68 million in additional savings, with the company confirming its full-year target of EUR 180 million in additional annual savings. Care Delivery segment saw 4% organic growth, while Care Enablement grew 5%. The company maintained stable U.S. same market treatment development despite a severe flu season impact.
The company's net leverage ratio improved to 2.8x from 2.9x in Q4 2024. Fresenius Medical Care confirmed its 2025 outlook, expecting positive low-single-digit revenue growth and operating income growth of high-teens to high-twenties percent.
Fresenius Medical Care (FMS) has released its 2024 Annual Report and Sustainability Statement, showcasing significant progress in its three-year transformation journey. The company achieved 4% organic revenue growth and 18% operating income growth on an outlook base in 2024.
Key sustainability achievements include maintaining a high global patient Net Promoter Score of 72, conducting 22 clinical studies, and publishing 165 scientific research documents. The company operates 3,675 dialysis clinics serving approximately 299,000 patients worldwide.
Environmental initiatives resulted in a 25% reduction in Scope 1 and 2 emissions compared to 2020, with over 100 energy efficiency opportunities identified at production sites. The company also strengthened its financial foundation by reducing debt and increasing dividends, positioning itself for enhanced earnings growth in 2025.
Fresenius Medical Care reported an 18% increase in operating income for 2024, reaching the upper end of its outlook range. The company achieved organic revenue growth of 4%, driven by Care Enablement and Care Delivery segments. U.S. same market treatment growth turned positive for the full year. The FME25 program delivered EUR 567 million in savings, surpassing the target, and the 2025 goal was raised to EUR 750 million. Reported net income grew by 8%, and the net financial leverage ratio improved from 3.2x to 2.9x. A 21% dividend increase is planned.
Fresenius Medical Care's strategic plan included exiting non-core assets, impacting revenue by EUR 306 million and operating income by EUR 288 million. The company reduced net financial debt by 9% to EUR 9.8 billion. Group revenue increased by 2% in Q4 2024 to EUR 5,085 million, with Care Enablement revenue growing by 11%. Operating income for Q4 decreased by 39%, but on an outlook base, it increased by 31%.
For 2025, Fresenius Medical Care expects revenue growth to be positive to a low-single digit percent rate and operating income to grow by a high-teens to high-twenties percent rate. The company treated 299,352 patients in 3,675 clinics worldwide as of December 31, 2024.
Fresenius Medical Care (XETRA: FME; NYSE: FMS), a global leader in renal disease care, announced the divestment of select assets of its wholly owned Spectra Laboratories to Quest Diagnostics (NYSE: DGX). Under the agreement, Quest will acquire laboratory assets focused on renal-specific testing in the U.S. Additionally, Quest will provide comprehensive dialysis-related lab and water testing services to Fresenius Medical Care's clinics in the U.S.
This acquisition will allow Quest to enhance its portfolio with dialysis-related water testing capabilities. The deal is expected to bring operational efficiencies to Fresenius Medical Care and leverage Quest's national scale, reducing transportation times and speeding up results reporting. Financial terms were not disclosed, and the acquisition is expected to close in the second half of 2025, with service transitions completing by early 2026.
Fresenius Medical Care is in the second year of a three-year strategic turnaround plan, focusing on optimizing its portfolio by divesting non-core and dilutive assets. Chronic kidney disease affects approximately 35.5 million people in the U.S., with over 800,000 receiving dialysis. This transaction aligns with Fresenius Medical Care's strategy to concentrate on its core business of providing dialysis care.